Interleukin-6 inhibitors: from the therapy of immuno-inflammatory rheumatic diseases to use in COVID-19-Reference-Cited by-同舟云学术

Interleukin-6 inhibitors: from the therapy of immuno-inflammatory rheumatic diseases to use in COVID-19

Published:2022-07-06 Issue:11 Volume: Page:88-94
ISSN:2658-5790
Container-title:Meditsinskiy sovet = Medical Council
language:
Short-container-title:Medicinskij sovet

Author:

Muravyeva N. V.¹^ORCID,Belov B. S.¹^ORCID

Affiliation:

1. Nasonova Research Institute of Rheumatology

Abstract

The key role in the development of chronic autoimmune inflammation is played by pro-inflammatory cytokines, in particular, interleukin 6 (IL-6). The introduction into clinical practice of monoclonal antibodies inhibiting IL-6 is a significant event in rheumatology and is currently considered as a promising direction in the treatment of immuno-inflammatory rheumatic diseases. The first inhibitor of IL-6 (IL-6), which entered the practice of rheumatologists, was tocilizumab (TCZ), the second – sarilumab (SAR). Numerous studies have shown the high effectiveness of iIL-6: the use of drugs leads to a rapid decrease in the clinical manifestations of rheumatoid arthritis (RA) and a decrease in laboratory signs of inflammation, contributing to the achievement of low activity or remission, improves the quality of life of patients, and also slows down the X-ray progression of the disease. At the same time, iIL-6 has a satisfactory safety profile. The universal problem of our time – the pandemic of a new coronavirus infection – has led to attempts to use IL-6 in patients with severe and critical disease, since IL-6 plays an important role in the pathogenesis of COVID-19, which is confirmed by the results of numerous studies. However, data on the efficacy and safety of these drugs in COVID-19 are contradictory, which requires conducting larger-scale controlled studies. This review examines the issues of the effectiveness and safety of TCZ and SAR in rheumatological patients and in patients with COVID-19. The review is illustrated with examples from real clinical practice.

Publisher

Remedium, Ltd.

Subject

General Medicine

Reference49 articles.

1. Nasonov E.L., Lila A.M. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes. Rheumatology Science and Practice. 2017;(6):590–599. (In Russ.) Available at: https://rsp.mediar-press.net/rsp/article/view/2461.

2. Hunter C.A., Jones S.A. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448–457. https://doi.org/10.1038/ni.3153.

3. Calabrese L.H., Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol. 2014;10(12):720–727. https://doi.org/10.1038/nrrheum.2014.127.

4. Nasonov E.L., Stanislav M.L., Raskina T.A., Kuropatkin G.V., Shirinsky I.V., Rebrov A.P. et al. Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study). Rheumatology Science and Practice. 2019;(2):142–148. (In Russ.) Available at: https://rsp.mediar-press.net/rsp/article/view/2696.

5. Nishimoto N., Hashimoto J., Miaysaka N., Yamamoto K., Kawai S., Takeuchi T. et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162–1167. https://doi.org/10.1136/ard.2006.068064.